Haemonetics (STU:HAZ) EV-to-EBIT : 32.62 (As of May. 11, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Haemonetics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Haemonetics's Enterprise Value is €5,144 Mil. Haemonetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €158 Mil. Therefore, Haemonetics's EV-to-EBIT for today is 32.62.

The historical rank and industry rank for Haemonetics's EV-to-EBIT or its related term are showing as below:

STU:HAZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -517.46 Med: 44.52 Max: 254.21
Current: 32.58

During the past 13 years, the highest EV-to-EBIT of Haemonetics was 254.21. The lowest was -517.46. And the median was 44.52.

STU:HAZ's EV-to-EBIT is ranked worse than
70.77% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs STU:HAZ: 32.58

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Haemonetics's Enterprise Value for the quarter that ended in Dec. 2023 was €4,556 Mil. Haemonetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €158 Mil. Haemonetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.46%.

Haemonetics EV-to-EBIT Historical Data

The historical data trend for Haemonetics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics EV-to-EBIT Chart

Haemonetics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-EBIT

Get a 7-Day Free Trial

55.59

51.47

68.75

46.39

29.84

Haemonetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															32.22	29.84	26.81	29.59	29.49

Competitive Comparison of Haemonetics's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Haemonetics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Haemonetics's EV-to-EBIT falls into.

Haemonetics EV-to-EBIT Calculation

Haemonetics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5143.753	/	157.696
	=	32.62

Haemonetics's current Enterprise Value is €5,144 Mil.
Haemonetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €158 Mil.

Haemonetics (STU:HAZ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Haemonetics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	157.696	/	4556.2855
	=	3.46 %

Haemonetics's Enterprise Value for the quarter that ended in Dec. 2023 was €4,556 Mil.
Haemonetics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €158 Mil.

Haemonetics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Haemonetics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (STU:HAZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (STU:HAZ) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

HAE:USA

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (STU:HAZ) Headlines

No Headlines